Citation Impact
Citing Papers
Intravitreal Bevacizumab for Retinopathy of Prematurity
2011
Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity
2011 Standout
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
2013 Standout
The epidemics of myopia: Aetiology and prevention
2017 Standout
Retinopathy of prematurity
2013 Standout
Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction
2011
DELAYED RECURRENT NEOVASCULARIZATION AND PERSISTENT AVASCULAR RETINA FOLLOWING INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY
2013
Screening Examination of Premature Infants for Retinopathy of Prematurity
2018 Standout
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
The Association between Time Spent Outdoors and Myopia in Children and Adolescents
2012 Standout
Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity
2011
Role of intravitreal bevacizumab in adult onset Coats’ disease
2011
Outdoor activity and myopia in Singapore teenage children
2009
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity
2012
Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment
2014
Works of San‐Ni Chen being referenced
THE EFFECT OF INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF COATS DISEASE IN CHILDREN
2010
Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in Taiwan
2010
PEDIATRIC RHEGMATOGENOUS RETINAL DETACHMENT IN TAIWAN
2006
An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan
2012